线粒体分裂抑制剂Mdivi-1保护器官功能并延长未控制性失血性休克大鼠的治疗窗口
本研究在大鼠未控制性失血性休克(UHS)模型中,于确定性止血前给予线粒体分裂抑制剂Mdivi-1(0.25 mg/kg、0.5 mg/kg、1 mg/kg),以乳酸林格液加羟乙基淀粉(130/0.4)为对照。结果显示,与常规复苏液相比,Mdivi-1显著减少失血量和液体需求,改善降压复苏期间的重要器官功能,提高动物生存率并降低早期死亡发生率;同时减轻氧化应激损伤、减少线粒体损伤,恢复心肌线粒体结构及心、肝、肾、肠的线粒体功能。Mdivi-1还延长了降压复苏的维持时间,在将降压复苏延长至2小时后仍改善大鼠生存。作者认为其机制可能是抑制过度线粒体分裂和氧化应激。
要点
- 在UHS模型大鼠确定性止血前给予Mdivi-1(0.25、0.5、1 mg/kg),较乳酸林格液加羟乙基淀粉(130/0.4)显著减少失血量和液体需求。
- Mdivi-1改善降压复苏(50–60 mm Hg)期间重要器官功能,提高动物生存率并降低早期死亡发生率。
- Mdivi-1减轻氧化应激损伤、减少线粒体损伤,恢复心肌线粒体结构及心、肝、肾、肠线粒体功能。
- Mdivi-1延长降压复苏的维持时间,在降压复苏延长至2小时后仍改善大鼠生存,将治疗窗口延长至2小时。
- 作者认为机制可能是抑制过度线粒体分裂和氧化应激、改善线粒体结构与功能。
适用人群与场景
- 未控制性失血性休克(UHS)模型大鼠,在确定性止血治疗前接受干预。
处置流程与药物剂量
- 在确定性止血前给予Mdivi-1 0.25 mg/kg、0.5 mg/kg或1 mg/kg(原文未写明给药途径与频次)。
- 对照复苏液为乳酸林格液加羟乙基淀粉(130/0.4)。
- 降压复苏目标为50–60 mm Hg,并评估将降压复苏延长至2小时的效果。
研究设计与关键结果
- 研究类型为大鼠UHS模型实验;在确定性止血前给予Mdivi-1(0.25、0.5、1 mg/kg),对照为乳酸林格液加羟乙基淀粉(130/0.4)。
- 与常规复苏液相比,Mdivi-1显著减少失血量和液体需求,改善降压复苏期间重要器官功能,提高动物生存率并降低早期死亡发生率。
- Mdivi-1显著减轻氧化应激损伤、减少线粒体损伤,恢复心肌线粒体结构及心、肝、肾、肠线粒体功能。
- Mdivi-1延长降压复苏维持时间,并在降压复苏延长至2小时后改善大鼠生存。
- 作者结论:Mdivi-1将UHS模型大鼠创伤性失血性休克治疗窗口显著延长至2小时。
证据类型、等级与局限
- 证据类型:大鼠UHS模型实验研究(动物实验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为UHS模型大鼠研究,Mdivi-1(0.25、0.5、1 mg/kg)在确定性止血前给药可减少失血量和液体需求、改善器官功能与生存,并将治疗窗口延长至2小时;作者认为机制可能是抑制过度线粒体分裂和氧化应激。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Aim: This study aimed to elucidate whether the application of the mitochondrial division inhibitor Mdivi-1 can protect organ function and prolong the treatment window for traumatic hemorrhagic shock. Methods: Before definitive hemostasis treatment, Mdivi-1 (0.25 mg/kg, 0.5 mg/kg, and 1 mg/kg) was administered to uncontrolled hemorrhagic shock (UHS) model rats. Lactate Ringer's solution plus hydroxyethyl starch (130/0.4) was used as a control. The effects of Mdivi-1 on blood loss; fluid demand; survival time; vital organ function; myocardial mitochondrial structure; mitochondrial function of the heart, liver, kidney, and intestine; and oxidative stress at 1 h after hypotensive resuscitation (50-60 mm Hg) were investigated. In addition, we investigated the effect of varying doses of Mdivi-1 on the maintenance time of hypotensive resuscitation without definitive hemostasis and the beneficial effect of Mdivi-1 after prolonging the duration of hypotensive resuscitation to 2 h. Results: Compared to conventional resuscitative fluid, Mdivi-1 significantly reduced blood loss and fluid demand, improved important organ functions during hypotensive resuscitation, improved animal survival, and reduced the incidence of early death. Mdivi-1 significantly alleviated oxidative stress injury, reduced mitochondrial damage, and restored myocardial mitochondrial structure and mitochondrial function of the heart, liver, kidney, and intestine. In addition, Mdivi-1 increased the maintenance time of hypotensive resuscitation and improved rat survival after the duration of hypotensive resuscitation was prolonged to 2 h. Conclusion: Mdivi-1 significantly prolonged the treatment window for traumatic hemorrhagic shock to 2 h in UHS model rats. The underlying mechanism may be that Mdivi-1 inhibits excessive mitochondrial fission and oxidative stress and improves the structure and function of mitochondria.
参考来源
- Hu Y, Fang H, Tan L, et al. THE MITOCHONDRIAL DIVISION INHIBITOR MDIVI-1 PROTECTED ORGAN FUNCTION AND EXTENDED THE TREATMENT WINDOW IN RATS WITH UNCONTROLLED HEMORRHAGIC SHOCK. Shock. 2024. PMID: 39185710. doi:10.1097/SHK.0000000000002459
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。